Atrium Therapeutics, Inc.

RNA · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

–

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.3%

Institutions85.2%

Public / Other

Income Statement

	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$9.56M	$9.22M	$9.33M	$6.79M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$235.60M	–	–	-$44.28M
Operating income as a percentage of revenue.	-2464.4%	–	–	-652.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$212.22M	-$174.00M	-$118.01M	-$44.35M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-3.00	$-2.85	$-2.05
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-3.00	–	–

Balance Sheet

	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$185.08M	$340.40M	$320.45M	$321.46M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$628.55M	$638.80M	$427.58M	$333.90M
Everything the company owes — debt, unpaid bills, and other obligations.	$127.79M	$60.73M	$46.15M	$27.68M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$500.76M	$578.08M	$381.43M	$306.22M

Cash Flow Statement

	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$119.06M	-$136.27M	-$94.81M	-$37.12M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$4.23M	$2.82M	$3.74M	$1.09M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$123.29M	-$139.09M	-$98.55M	-$38.21M

	You	Peer avg
P/E	–	3.8
Revenue Growth	-21.9%	+21.2%
ROE	–	-55.2%

Atrium Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison